PMC:7696151 / 85396-85635
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2535 | 97-105 | Species | denotes | patients | Tax:9606 |
| 2549 | 38-41 | Chemical | denotes | HCQ | MESH:D006886 |
| 2550 | 175-187 | Chemical | denotes | temozolomide | MESH:D000077204 |
| 2551 | 212-215 | Chemical | denotes | HCQ | MESH:D006886 |
| 2570 | 82-90 | Disease | denotes | toxicity | MESH:D064420 |
| 2571 | 122-130 | Disease | denotes | melanoma | MESH:D008545 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T212 | 122-130 | Phenotype | denotes | melanoma | http://purl.obolibrary.org/obo/HP_0002861 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T543 | 0-239 | Sentence | denotes | The same authors further assessed the HCQ anticancer properties and dose-limiting toxicity on 40 patients with metastatic melanoma, by administering a dose intense regimen of temozolomide and escalating doses of HCQ (200–1200 mg/day p.o.). |